Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
India flag India · Delayed Price · Currency is INR
1,566.00
-45.30 (-2.81%)
Last updated: Nov 16, 2026, 3:29 PM IST

Symbiotec Pharmalab Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
1,2651,099967.841,002234.86775.27
Depreciation & Amortization
758.85532.83431.01388.22285.22258.28
Loss (Gain) From Sale of Assets
10.59-1.192.73-0.07-0.250.61
Asset Writedown & Restructuring Costs
-----3.11
Loss (Gain) From Sale of Investments
--10.1--0.03-0.06
Loss (Gain) on Equity Investments
--1.5513.6610.75-2.4
Stock-Based Compensation
22.797.4642.93---
Provision & Write-off of Bad Debts
-----6.677.92
Other Operating Activities
-130.2142.73284.3-25.2228.21-16.74
Change in Accounts Receivable
-1,462-593.67-719.78-301.2182.15-221.86
Change in Inventory
-418.72245.71743.35-920.1318.86-200.14
Change in Accounts Payable
792.56215.43-1,3151,699-74.45-438.48
Change in Other Net Operating Assets
109.17107.8123.3618.813.7311.6
Operating Cash Flow
948.611,746472.561,875692.38177.11
Operating Cash Flow Growth
-269.46%-74.80%170.81%290.93%-

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-2,291-2,257-3,081-2,098-2,244-723.5
Sale of Property, Plant & Equipment
-0.6913.2-0.440.850.04
Investment in Securities
-19.08-28.758.48-27.3228.67396.3
Other Investing Activities
3.873.447.4960.5314.5210.72
Investing Cash Flow
-2,307-2,269-3,065-2,064-2,200-316.44

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
-572.071,784-419.52179.63
Long-Term Debt Issued
-253.211,306845.981,113-
Total Debt Issued
1,715825.283,089845.981,532179.63
Short-Term Debt Repaid
----549.79--
Long-Term Debt Repaid
--2,383-152.07-4.48-1.7-8.39
Lease Payments
-7.49-9.1-2.43-1.58-1.7-1.1
Total Debt Repaid
-3,541-2,383-152.07-554.27-1.7-8.39
Net Debt Issued (Repaid)
-1,826-1,5582,937291.711,531171.24
Issuance of Common Stock
3,6822,182----
Other Financing Activities
-311.76-263.99-155.62-73.23-69.12-19.84
Financing Cash Flow
1,545359.872,782218.481,461151.4

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Cash Flow
186.61-163.5188.9529.44-46.1112.07

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-1,342-511.26-2,609-222.69-1,552-546.39
Free Cash Flow Growth
------
Free Cash Flow Margin
-13.86%-5.88%-34.71%-3.11%-27.39%-8.01%
Free Cash Flow Per Share
-21.89-8.84-46.78-4.00-28.37-9.99
Levered Free Cash Flow
--465.47-2,495-202.58-1,530-
Unlevered Free Cash Flow
--315.27-2,407-166.67-1,496-
Free Cash Flow After Leases
-1,350-520.36-2,611-224.27-1,553-547.49

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
258.61263.99155.6273.2369.1219.84
Cash Income Tax Paid
659.64617.11348.27342.71166.64297.55
Change in Working Capital
-978.59-24.72-1,268496.68140.29-848.88